Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer

Trial Profile

Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs AGEN 2034 (Primary)
  • Indications Cervical cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Agenus
  • Most Recent Events

    • 03 Aug 2017 According to an Agenus media release, the company expects to complete dose-escalation for monotherapy, define optimal combination dose and collect safety and receptor occupancy data and recruit patients with second line cervical cancer in the second half of 2017.
    • 20 Apr 2017 According to an Agenus media release, preliminary safety and efficacy data are expected to be available within the next 9-12 months.
    • 20 Apr 2017 According to an Agenus media release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top